129 related articles for article (PubMed ID: 35836325)
1. Denials, Dilly-dallying, and Despair: Navigating the Insurance Labyrinth to Obtain Medically Necessary Medications for Pediatric Inflammatory Bowel Disease Patients.
Kahn SA; Bousvaros A
J Pediatr Gastroenterol Nutr; 2022 Oct; 75(4):418-422. PubMed ID: 35836325
[TBL] [Abstract][Full Text] [Related]
2. Profile of denials of durable medical equipment for SCI patients by third party payers.
Donovan WH; Carter RE; Wilkerson MA
Am J Phys Med; 1987 Oct; 66(5):238-43. PubMed ID: 3434625
[TBL] [Abstract][Full Text] [Related]
3. Effective advocacy for patients with inflammatory bowel disease: communication with insurance companies, school administrators, employers, and other health care overseers.
Jaff JC; Arnold J; Bousvaros A
Inflamm Bowel Dis; 2006 Aug; 12(8):814-23. PubMed ID: 16917236
[TBL] [Abstract][Full Text] [Related]
4. Barriers From Third-Party Payers to Biologic Use in Pediatric Inflammatory Bowel Disease.
Lepus CA; Hyams JS
JPGN Rep; 2022 Aug; 3(3):e215. PubMed ID: 37168642
[TBL] [Abstract][Full Text] [Related]
5. Discordance Between Inflammatory Bowel Disease Specialists and Insurance Authorization Denials-A Survey of Specific Inflammatory Bowel Disease Treatment Scenarios.
Naritsin A; Mehta N; Pellish R
Crohns Colitis 360; 2024 Jan; 6(1):otad082. PubMed ID: 38264509
[TBL] [Abstract][Full Text] [Related]
6. Preauthorization Inconsistencies Prevail in Reduction Mammaplasty.
Boyd CJ; Hemal K; Cohen JM; Daar DA; Gwin J; Zupko K; Karp NS
Plast Reconstr Surg Glob Open; 2023 Oct; 11(10):e5361. PubMed ID: 37900990
[TBL] [Abstract][Full Text] [Related]
7. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
Murry L; Gerleman B; Urick B; Urmie J
J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
[TBL] [Abstract][Full Text] [Related]
8. Coding for effective denial management.
Miller J; Lineberry J
Radiol Manage; 2004; 26(1):18-21. PubMed ID: 14994832
[TBL] [Abstract][Full Text] [Related]
9. Insurance Denials and Patient Treatment in a Large Academic Radiation Oncology Center.
Shin JY; Chino F; Cuaron JJ; Washington C; Jablonowski M; McBride S; Gomez DR
JAMA Netw Open; 2024 Jun; 7(6):e2416359. PubMed ID: 38865128
[TBL] [Abstract][Full Text] [Related]
10. Prior authorization as a utilization management tool for elective superficial venous procedures results in high administrative cost and low efficacy in reducing utilization.
Lee V; Berland T; Jacobowitz G; Rockman C; Sadek M; Barfield M; Cayne N; Maldonado TS
J Vasc Surg Venous Lymphat Disord; 2020 May; 8(3):383-389.e1. PubMed ID: 31859243
[TBL] [Abstract][Full Text] [Related]
11. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
12. A proactive medical necessity review program reduces revenue loss associated with outpatient medical benefit drugs.
Hawes EM; Misita CP; Amerine LB; Francart SJ
Am J Health Syst Pharm; 2021 Aug; 78(17):1591-1599. PubMed ID: 33599737
[TBL] [Abstract][Full Text] [Related]
13. Multi-Institutional Analysis of Insurance Denial Patterns Within Rhinology.
Janz TA; Khan NS; Dhanda AK; Takashima M; Wu AW; Tang DM; Higgins TS; Ramanathan M; Ahmed OG
Am J Rhinol Allergy; 2024 Jul; 38(4):218-222. PubMed ID: 38544439
[TBL] [Abstract][Full Text] [Related]
14. Family reports of care denials for children enrolled in TennCare.
Valet RS; Kutny DF; Hickson GB; Cooper WO
Pediatrics; 2004 Jul; 114(1):e37-42. PubMed ID: 15231971
[TBL] [Abstract][Full Text] [Related]
15. Insurance Appeals for Pediatric Reconstructive Surgery: A Micro Cost Analysis and How-to Guide.
Braun TL; Braun JL; Hernandez C; Monson LA
Ann Plast Surg; 2018 Mar; 80(3):198-204. PubMed ID: 29389708
[TBL] [Abstract][Full Text] [Related]
16. Rationing by Inconvenience: How Insurance Denials Induce Administrative Burdens.
Yaver M
J Health Polit Policy Law; 2024 Feb; ():. PubMed ID: 38324347
[TBL] [Abstract][Full Text] [Related]
17. Physicians' interactions with third-party payers: is deception necessary?
Bogardus ST; Geist DE; Bradley EH
Arch Intern Med; 2004 Sep; 164(17):1841-4. PubMed ID: 15451757
[TBL] [Abstract][Full Text] [Related]
18. Strategies for appeals of PRO payment denials.
Manning MM; Miller WJ
Med Staff Couns; 1990; 4(4):21-5. PubMed ID: 10107508
[TBL] [Abstract][Full Text] [Related]
19. Preventing & dealing with ESRD claim denials.
Parker S; Davidson N; Gagliano R
Nephrol News Issues; 2002 Oct; 16(11):18-21, 25-6. PubMed ID: 12400188
[TBL] [Abstract][Full Text] [Related]
20. Insurance Denials in Reduction Mammaplasty: How Can We Serve Our Patients Better?
Boukovalas S; Boson AL; Padilla PL; Sljivich M; Tran JP; Spratt H; Phillips LG
Plast Reconstr Surg; 2020 Aug; 146(2):127e-136e. PubMed ID: 32740569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
